Clinical Study
Recombinant Human Thrombopoietin Treatment Promotes Hematopoiesis Recovery in Patients with Severe Aplastic Anemia Receiving Immunosuppressive Therapy
Table 1
Patients’ characteristics.
| | With rhTPO | Without rhTPO | value |
| Patients number | 40 | 48 | | Median age (year, range) | 36 (16–66) | 32 (16–68) | 0.74 | Gender, male/female | 18/22 | 27/21 | 0.39 | Severity of disease | | | 0.51 | VSAA | 27 | 28 | | SAA | 13 | 20 | | Neutrophil counts, ×109/L (median, range) | 0.15 (0–1.31) | 0.16 (0–1.47) | 0.46 | Platelet counts, ×109/L (median, range) | 9 (0–28) | 10 (0–34) | 0.75 | Reticulocyte counts, ×109/L (median, range) | 18 (0.3–43) | 14 (0.4–50) | 0.62 | Lymphocyte counts, ×109/L (median, range) | 1.48 (0.41–4.17) | 1.52 (0.39–3.99) | 0.87 | Interval from diagnosis to ATG (median, range), days | 19 (1–416) | 21 (1–839) | 0.58 |
|
|